Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · May 28, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to diagnose lung cancer by checking for changes in DNA that can be found through a simple blood test. Researchers hope that this study will help develop a reliable method for detecting lung cancer early, which could benefit many people in the future. The study is open to adults aged 18 and older who are patients at the University of Maryland Baltimore Washington Medical Center and can speak and understand English.

If you choose to participate, you will provide blood samples during your regular clinic visits, and your medical records will be reviewed. You will also fill out some questionnaires at different times throughout the study, which will last about five years. The study is currently recruiting participants, so if you're interested, this could be an opportunity to contribute to important research in lung cancer diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years old or older
• • Patient at University of Maryland Baltimore Washington Medical Center
• • Willing and able to consent to study procedures listed in the protocol
• • Ability to speak and understand English
• Exclusion Criteria:
• • Younger than 18 years old
• • Patient not cared for at University of Maryland Baltimore Washington Medical Center
• • Unable to consent to study procedures listed in the protocol
• • Unable to speak or understand English